Trial Profile
Phase 3 Study of Efficiency, Safety and Portability of Gene Therapy Drug Neovasculgen (DNA Encoding the 165-amino-acid Isoform of Human Vascular Endothelial Growth Factor (pCMV - VEGF165) for Peripheral Arterial Disease Complex Treatment
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vascular endothelial growth factor-165 gene therapy (Neovasculgen) (Primary)
- Indications Peripheral arterial disorders
- Focus Therapeutic Use
- 20 Jul 2015 New trial record